City Therapeutics
Latest round
- Series B
Last raised
- Jun 2026
Total raised
- $235M
Investors
- 12
About City Therapeutics
D., City Therapeutics Inc. operates as a provider of engineered small interfering RNAs (siRNAs) to biotechnology firms and healthcare organizations for developing innovative RNAi therapies. In June 2026, City Therapeutics Inc. The company provides a wide range of biotechnology solutions, such as small interfering RNAs (siRNAs), engineered RNAi trigger molecules, targeting ligands for enhanced cellular uptake, and advanced therapeutic targets. Additionally, the firm also provides services such as clinical development optimization for RNAi-based medicines and support for therapeutic target identification.
Who invested in City Therapeutics
12 investors across 2 rounds
See all investors in City Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about City Therapeutics
Who invested in City Therapeutics?
City Therapeutics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has City Therapeutics raised?
City Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did City Therapeutics last raise money?
City Therapeutics's most recent round on record is a Series B, in Jun 2026.
What does City Therapeutics do?
City Therapeutics is a biotechnology company.
Where is City Therapeutics headquartered?
City Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like City Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at City Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like City Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.